Supernus completes merger with Indivior
SUPN•Supernus Pharmaceuticals completed its merger with Indivior on Nov. 2, 2026, creating a central nervous system drugmaker that will trade as Supernus under SUPN. Indivior shareholders own approximately 56.5% of the combined company and will receive a $1 billion special cash dividend.
1. Merger terms
The combined company will begin trading on the Nasdaq Global Market under the SUPN symbol on Nov. 3. Supernus shareholders received 1.5401 Indivior common shares per share and own approximately 43.5% of the combined company. The $1 billion dividend to Indivior shareholders is funded by a $650 million Citibank term loan facility and existing combined-company cash.
